Global Molecular Effects of Tocilizumab Therapy in Rheumatoid Arthritis Synovium

Ducreux, Julie; Durez, Patrick; Galant, Christine; Toukap, A. Nzeusseu; Eynde, Benoı̂t Van den; Houssiau, Frédéric; Lauwerys, Bernard

doi:10.1002/art.38202

Cited by 63 publications

(66 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thereafter, a series of elegant studies using either arthroscopic or ultrasound guided synovial [21]. Synovial studies are more limited but demonstrate that IL-6R blockade leads to reduction in T cell activation markers and chemokine expression but also induced pro-repair gene sets [22]. These changes are discrete when compared with those noted upon B cell depletion and TNF inhibition suggesting some degree opf specificity in synovial changes upon IL-6R blockade.…”

Section: Tnf and Il-6 As Critical Disease Effector Pathwaysmentioning

confidence: 99%

Pathogenetic insights from the treatment of rheumatoid arthritis

2017

View full text Add to dashboard Cite

show abstract

Section: Tnf and Il-6 As Critical Disease Effector Pathwaysmentioning

confidence: 99%

Pathogenetic insights from the treatment of rheumatoid arthritis

2017

View full text Add to dashboard Cite

show abstract

“…They noted that many inflammatory conditions are driven by multiple pathways, and reasoned that it would make sense to block at least two of them simultaneously. 90, 91, 92 TNF and IL-6 blocking agents are both approved in RA and with similar efficacy (ADACT trial, NCT01119859). It is believed that IL-6 is more important in the systemic part of the disease whereas TNF controls local inflammation.…”

Section: Affimabsmentioning

confidence: 99%

Affibody molecules as engineered protein drugs

Frejd

Kim²

2017

Exp Mol Med

183

147

View full text Add to dashboard Cite

Affibody molecules can be used as tools for molecular recognition in diagnostic and therapeutic applications. There are several preclinical studies reported on diagnostic and therapeutic use of this molecular class of alternative scaffolds, and early clinical evidence is now beginning to accumulate that suggests the Affibody molecules to be efficacious and safe in man. The small size and ease of engineering make Affibody molecules suitable for use in multispecific constructs where AffiMabs is one such that offers the option to potentiate antibodies for use in complex disease.

show abstract

“…To test the applicability of network-based proximity by DMARDs, we imported the gene expression dataset of RA synovial tissues, which was obtained from 12 RA patients on two separate occasions before and after a 12-week TZCM treatment (GSE45867) [45]. To compare the paired samples before and after TZCM treatment, ssGSEA was used to generate enrichment scores for gene sets of GO terms by RA disease module.…”

Section: Module-driven Validation Of Network-based Proximity By Tocilmentioning

confidence: 99%